We have a diversified and balanced clinical development pipeline covering multiple therapeutic areas, including CNS, cardiovascular and immunological disorders, as well as orphan diseases.

Compound Mechanism of Action Target Indication Status Webcasts
         
Aprocitentan*  Dual endothelin receptor antagonist Resistant hypertension management Phase 3 Phase 3 initiation
Clazosentan** Endothelin receptor antagonist Vasospasm associated with aneurysmal subarachnoid hemorrhage (aSAH) Advancing to Phase 3 Phase 3 advancing
Lucerastat Glucosylceramide synthase inhibitor Fabry disease Phase 3 Phase 3 initiation
Nemorexant Dual orexin receptor antagonist Insomnia Phase 3 Phase 3 initiation
Cenerimod S1P1 receptor modulator Systemic lupus erythematosus Phase 2  
Vamorolone*** Dissociative steroid Duchenne muscular dystrophy Phase 2  
ACT-246475 P2Y12 receptor antagonist Acute coronary syndrome (ACS) Phase 2  
ACT-774312 CRTH2 receptor antagonist Nasal polyposis Advancing to Phase 2  
ACT-519276 GBA2/GCS inhibitor Orphan CNS diseases Phase 1  
ACT-539313 Selective orexin 1 receptor antagonist Anxiety Phase 1  
ACT-709478 T-type calcium channel blocker Epilepsy Phase 1  


* In collaboration with Janssen Biotech to jointly develop and solely commercialize aprocitentan worldwide
** In Japan, market registration trials are being conducted, with results expected in the second half of 2018
*** Idorsia has exclusive option to worldwide rights to ReveraGen’s Vamorolone.